BioSpace News Archive

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that Jeff Baxter, VBI’s President and CEO, will participate in an analyst-led fireside chat at the 32nd Annual Oppenheimer Healthcare Conference.

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today announced that it will highlight its therapeutic A-to-I(G) RNA base editing oligonucleotides (“AIMers”) at two upcoming scientific and industry meetings.

Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel irreversible covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, today announced that it is scheduled to participate in a fireside chat at the Oppenheimer 32nd Annual Virtual Healthcare Conference.

EXUMA Biotech, Corp., a clinical-stage biotechnology company discovering and developing cell and gene therapies for liquid and solid tumors, announced that preclinical data from its novel, subcutaneous CAR-TaNK therapy for hematological tumors, and in vivo engineered CAR gene therapy program (GCAR), will be presented in two posters at the American Association for Cancer Research (AACR) Annual Meeting.

The Institute for Molecular Medicine (IMM), today announced that it was awarded a $12 million grant from the National Institute on Aging (NIA) division of the U.S. National Institutes of Health (NIH) to support clinical trials of its beta-amyloid (Aβ) vaccines based on DNA (AV-1959D) and recombinant protein (AV-1959R) for the prevention of Alzheimer’s disease (AD).

The National Comprehensive Cancer Network® announced the publication of new expert consensus recommendations to address routine problems that can occur during prescribing, receiving, storing, preparing, and delivering investigational drugs.

SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that the Company will participate in the Canaccord Musculoskeletal Conference on Tuesday, March 22, 2022 beginning at 2:30 pm ET.

Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), announced today that it has completed enrollment and dosing in Phase 2b viral challenge study (RVL-VRL01) to evaluate the efficacy of intranasal REVTx-99 for the preventive treatment of H3N2 influenza (influenza A) infection in healthy humans.

Rockwell Medical, Inc. presented survey findings in oral and poster presentations at the National Home Infusion Association’s 2022 Annual Conference, taking place March 12 through 16, 2022 in Nashville, Tennessee.

Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, and Kymera Therapeutics, a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD), announced today that they are broadly collaborating across preclinical studies and clinical trials.